Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (NASDAQ: NTRA) is a diagnostic and research company in the medical laboratories industry, focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. The Natera news feed on Stock Titan highlights company announcements, clinical data readouts, collaborations, and financial updates that reflect how its testing platforms are used in practice and research.
Recent news has featured advances in molecular residual disease (MRD) testing with Signatera, including new multi-modal AI models that integrate longitudinal circulating tumor DNA, clinical data, digital pathology, and tumor sequencing to refine recurrence risk assessment and outcomes prediction. Natera also reports on large clinical studies and trial analyses in colorectal cancer and breast cancer, where Signatera is used to evaluate MRD, predict treatment response, and support risk stratification.
In women’s health, news items include the launch and validation of Fetal Focus, a single-gene non-invasive prenatal test that uses cell-free DNA from maternal blood to assess inherited conditions when partner testing is not available, as well as updates related to the broader prenatal and carrier screening portfolio. Organ health news may cover the use of Natera’s Prospera test in transplant rejection assessment and related research.
Investors and clinicians can also follow Natera’s announcements about AI collaborations, such as its work with NVIDIA to scale multimodal AI foundation models, and corporate updates including preliminary financial results and participation in healthcare conferences. For those tracking NTRA, this news page provides a centralized view of developments across oncology, women’s health, organ health, and AI-enabled diagnostics.
Natera announced new data from the CIRCULATE-Japan trial, revealing a 75% detection rate of colorectal cancer recurrence from a single blood draw four weeks post-surgery. This update, presented at the SSO 2022 conference, indicates improved outcomes for patients identified through Natera's Signatera test. The CIRCULATE-Japan study is the largest clinical trial focusing on molecular residual disease in colorectal cancer, enrolling over 3,300 patients to date. Additionally, Natera activated the CIRCULATE-US trial to further explore MRD-guided treatment strategies.
Natera, Inc. (NASDAQ: NTRA) announced a $5 million investment in its stock by Roelof Botha, lead independent director and partner at Sequoia Capital, reflecting his confidence in the company’s future. Botha has worked closely with Natera for 15 years, emphasizing his commitment to its strategic and commercial execution. Additionally, Natera's executives and non-employee directors will convert their cash compensation to equity for the remainder of 2022. This move indicates a strong internal belief in the company's potential, focusing on genetic testing's role in healthcare.
A jury in Delaware District Court ruled that both CareDx and Natera engaged in false advertising. CareDx misled investors and physicians regarding its funding of a scientific publication, which it falsely claimed was independent. Additionally, there were no findings regarding the scientific validity of Natera's data. In parallel litigation, a federal court invalidated all patents that CareDx asserted against Natera, who is pursuing its own patent enforcement. Final monetary relief from the jury's decision is still pending.
Natera, Inc. (NASDAQ: NTRA) announced a significant change in compensation for its executive leaders and board of directors, who will receive stock instead of cash salaries for the remainder of 2022. This decision reflects their confidence in the company's strong fundamentals and business outlook. Key figures include CEO Steve Chapman, CFO Mike Brophy, and COO Bob Schueren, among others. Natera focuses on cell-free DNA testing across oncology, women's health, and organ health, emphasizing a commitment to personalized diagnostics.
Natera, Inc. (NASDAQ: NTRA) has achieved a significant milestone in its BESPOKE CRC study, enrolling over 1,000 patients across more than 100 sites in the U.S. The study focuses on the impact of Signatera, a custom ctDNA test, in managing colorectal cancer (CRC). Target enrollment is over 2,000 patients, with a follow-up period of up to 5 years. Investigators plan an interim analysis in late 2022. This study aims to provide real-world insights into personalized treatment decisions for CRC patients.
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, has announced an investor call on March 10, 2022, to address a recent misleading report by short sellers. CFO Mike Brophy will provide updates and clarify the misinformation. The call will be held at 4:00 a.m. PT (7:00 a.m. ET), with a live dial-in option available for participants. A replay of the webcast will be accessible post-event on Natera's investor relations site. Natera emphasizes its commitment to providing accurate genetic testing validated by extensive peer-reviewed research.
Natera, based in Austin, Texas, responded strongly to a report by Hindenburg Research, labeling it misleading and an attempt by short sellers to profit from negative sentiments. The company emphasizes its commitment to compliance and the efficacy of its testing procedures, supported by over 100 peer-reviewed studies involving more than 1.3 million patients. Natera highlights its high performance in recent studies and maintains an A+ BBB rating, demonstrating a focus on patient satisfaction and operational integrity.
Natera, Inc. (NTRA) reported Q4 2021 revenues of $173.0 million, a 53.9% increase year-over-year, with full-year revenues reaching $625.5 million, up 60%. Product revenues rose 51.1% in Q4, driven by a 48.7% increase in tests processed. However, total operating expenses surged 72.8% in Q4, leading to a net loss of $140.6 million or ($1.48) per share. The company holds $914.5 million in cash, forecasting 2022 revenues between $770 million and $790 million with an approximate gross margin of 46% to 48%.
Natera, Inc. (NASDAQ: NTRA) announced it will release its fourth quarter and year-end 2021 financial results on February 24, 2022, after market close. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and financial outlook. Natera is a leader in cell-free DNA testing, focused on oncology, women's health, and organ health. Their tests are backed by over 100 peer-reviewed publications, ensuring high accuracy, with operations in Texas and California.
Natera, Inc. (NASDAQ: NTRA) announced the results of a large real-world study confirming the effectiveness of its Prospera donor-derived cell-free DNA (dd-cfDNA) test for kidney transplant patients. Conducted across 33 clinics with 879 patients, the study reported a 64% positive predictive value in detecting active rejection among those with high-risk results. The findings, published in Transplantation Proceedings, indicate that dd-cfDNA testing can enhance physician decision-making in managing transplant patients. This adds to existing evidence supporting the Prospera test's clinical utility.